


pending.

Amended claim 1 and added claims 51-85 are clearly supported in the Specification. See, e.g., original claim 1 and claims 2-50. See also, page 50, line 1 to page 55, line 14, page 32, line 23 to page 33, line 16, page 34, line 23 to page 43, line 26 and page 31, lines 12-21.

Applicants request entry of the above amendments and allowance of the pending claims.

Respectfully submitted,



James F. Haley, Jr.
Reg. No. 27,794
Attorney for Applicants
Stanley D. Liang
Reg. No. 43,753
Agent for Applicants
FISH & NEAVE
Customer No. 1473
1251 Avenue of the Americas
New York, New York 10020-1104
Tel.: (212) 596-9000

100356217.022302

Appendix to Claim Amendment

1. (Amended) A method for treating multiple myeloma comprising administering to an individual a therapeutically effective amount of a composition comprising an antagonist of an interaction between an $\alpha 4$ subunit-bearing integrin and a ligand for an $\alpha 4$ subunit-bearing integrin, wherein said antagonist is a small molecule.

1003627-022102